Objective To analyse the effect on implementation of the International Guidelines for Clinical Treatment of Pressure Injuries within leadership-staff-performance improvement-information technology(LSPI)framework of quality improvement,therefore to provide theoretical insights in promoting the transformation of prevention and treatment practice guidelines to clinical practices.Methods A pre-and post-control study was in this study.A total of 101 005 inpatients admitted to our hospital between July 2019 and June 2020 were assigned to a control group,and the other 110 824 patients who were hospitalised between July 2020 and June 2021 were assigned to a trial group.The two groups were compared in terms of the promptness rate and accuracy of primary risk assessment,response rate of high-risk patients and incidence of pressure injury before and after implementation of the guideline.Results After implementation of the guideline,the promptness rate and the accuracy of primary risk assessment and the rate of preventive measures in high-risk patients increased from 86.73%to 96.25%,93.46%to 98.69%and 94.21%to 98.15%,respectively.The incidence of hospital pressure injury decreased from 0.77‰ to 0.29 ‰.All the differences were statistically significant(all P＜0.05).Conclusions Implementation of the International Guidelines for the Clinical Treatment of Pressure Injuries within the LSPI framework of quality improvement can improve the quality of process management in pressure injury and reduce the incidence of pressure injuries.Therefore,it can facilitate the guideline-based code of practice in the clinical practices.

Two patients (patient 1, a 61-year-old male; patient 2, a 58-year-old female) received red yeast rice 6 g once daily orally because of abnormal blood lipids. Patient 1 had schistosomal cirrhosis and cholestatic hepatitis, with triacylglycerol 5.32 mmol/L. After 26 days of oral administration of red yeast rice, the patient developed limb weakness, with creatine kinase (CK) 604 U/L. Red yeast rice was stopped immediately and 3 days later, the patient developed lower limb muscle soreness, with CK 117 748 U/L. After 12 days of treatments with dexamethasone and rehydration, his symptoms gradually disappeared, with CK 79 U/L. Patient 2 had acute hepatitis, with triacylglycerol 2.34 mmol/L. After 24 days of oral administration of red yeast rice, the patient developed weakness and muscle soreness in both lower limbs, with CK 52 222 U/L. Red yeast rice was stopped immediately, and after 12 days of treatments with methylprednisolone and hydration, her symptoms were improved, with CK 210 U/L.

Two patients (patient 1, a 61-year-old male; patient 2, a 58-year-old female) received red yeast rice 6 g once daily orally because of abnormal blood lipids. Patient 1 had schistosomal cirrhosis and cholestatic hepatitis, with triacylglycerol 5.32 mmol/L. After 26 days of oral administration of red yeast rice, the patient developed limb weakness, with creatine kinase (CK) 604 U/L. Red yeast rice was stopped immediately and 3 days later, the patient developed lower limb muscle soreness, with CK 117 748 U/L. After 12 days of treatments with dexamethasone and rehydration, his symptoms gradually disappeared, with CK 79 U/L. Patient 2 had acute hepatitis, with triacylglycerol 2.34 mmol/L. After 24 days of oral administration of red yeast rice, the patient developed weakness and muscle soreness in both lower limbs, with CK 52 222 U/L. Red yeast rice was stopped immediately, and after 12 days of treatments with methylprednisolone and hydration, her symptoms were improved, with CK 210 U/L.

Background::Erythropoietin is a glycoprotein that mainly regulates erythropoiesis. In patients with chronic renal failure with anemia, darbepoetin alfa can stimulate erythropoiesis, correct anemia, and maintain hemoglobin levels. This study was designed to demonstrate the efficacy and safety of darbepoetin alfa injections as being not inferior to epoetin alfa injections (Recombinant Human Erythropoietin injection, rHuEPO) when maintaining hemoglobin (Hb) levels within the target range (10.0-12.0 g/dL) for the treatment of renal anemia.Methods::Ninety-five patients were enrolled in this study from April 15, 2013 to April 10, 2014 at 25 sites. In this study, patients ( n = 95) aged 18-70 years were randomized into a once per week intravenous darbepoetin alfa group ( n = 56) and a twice or three times per week intravenous epoetin alfa group ( n = 39) for 28 weeks, who had anemia with hemoglobin levels between 6 g/dL and 10 g/dL due to chronic kidney disease (CKD) and were undergoing hemodialysis or hemofiltration with ESA-naive (erythropoiesis stimulating agent-naive). The primary efficacy profile was the mean Hb level (the non-inferiority margin was -1.0 g/dL, week 21-28); the secondary efficacy profiles were the Hb increase rate (week 0-4), the target Hb achievement cumulative rate and time, the change trends of the Hb levels, and the target Hb maintenance ratio. Adverse events (AEs) were observed and compared, and the efficacy and safety were analyzed between the two treatment groups. Additionally, the frequencies of dose adjustments between the darbepoetin alfa and epoetin alfa groups were compared during the treatment period. SAS? software version 9.2 was used to perform all statistical analyses. Descriptive statistics were used for all efficacy, safety, and demographic variable analyses, including for the primary efficacy indicators. Results::The mean Hb level was 11.3 g/dL in the darbepoetin alfa group and 10.7 g/dL in the epoetin alfa group, respectively; the difference of the lower limits of the 95% confidence intervals (CI) between the two groups was 0.1 g/dL (>-1.0 g/dL), and non-inferiority was proven; the Hb levels started to increase in the first four weeks at a similar increase rate; no obvious differences were observed between the groups in the target Hb achievement cumulative rates, and the Hb levels as well as the target Hb level maintenance rate changed over time. The incidence of AEs was 62.5% in the darbepoetin alfa group and 76.9% in the epoetin alfa group. All the adverse events observed in the study were those commonly associated with hemodialysis.Conclusion::Darbepoetin alfa intravenously once per week can effectively increase Hb levels and maintain the target Hb levels well, which makes it not inferior to epoetin alfa intravenously twice or three times per week. Darbepoetin alfa shows an efficacy and safety comparable to epoetin alfa for the treatment of renal anemia.

Background::Erythropoietin is a glycoprotein that mainly regulates erythropoiesis. In patients with chronic renal failure with anemia, darbepoetin alfa can stimulate erythropoiesis, correct anemia, and maintain hemoglobin levels. This study was designed to demonstrate the efficacy and safety of darbepoetin alfa injections as being not inferior to epoetin alfa injections (Recombinant Human Erythropoietin injection, rHuEPO) when maintaining hemoglobin (Hb) levels within the target range (10.0-12.0 g/dL) for the treatment of renal anemia.Methods::Ninety-five patients were enrolled in this study from April 15, 2013 to April 10, 2014 at 25 sites. In this study, patients ( n = 95) aged 18-70 years were randomized into a once per week intravenous darbepoetin alfa group ( n = 56) and a twice or three times per week intravenous epoetin alfa group ( n = 39) for 28 weeks, who had anemia with hemoglobin levels between 6 g/dL and 10 g/dL due to chronic kidney disease (CKD) and were undergoing hemodialysis or hemofiltration with ESA-naive (erythropoiesis stimulating agent-naive). The primary efficacy profile was the mean Hb level (the non-inferiority margin was -1.0 g/dL, week 21-28); the secondary efficacy profiles were the Hb increase rate (week 0-4), the target Hb achievement cumulative rate and time, the change trends of the Hb levels, and the target Hb maintenance ratio. Adverse events (AEs) were observed and compared, and the efficacy and safety were analyzed between the two treatment groups. Additionally, the frequencies of dose adjustments between the darbepoetin alfa and epoetin alfa groups were compared during the treatment period. SAS? software version 9.2 was used to perform all statistical analyses. Descriptive statistics were used for all efficacy, safety, and demographic variable analyses, including for the primary efficacy indicators. Results::The mean Hb level was 11.3 g/dL in the darbepoetin alfa group and 10.7 g/dL in the epoetin alfa group, respectively; the difference of the lower limits of the 95% confidence intervals (CI) between the two groups was 0.1 g/dL (>-1.0 g/dL), and non-inferiority was proven; the Hb levels started to increase in the first four weeks at a similar increase rate; no obvious differences were observed between the groups in the target Hb achievement cumulative rates, and the Hb levels as well as the target Hb level maintenance rate changed over time. The incidence of AEs was 62.5% in the darbepoetin alfa group and 76.9% in the epoetin alfa group. All the adverse events observed in the study were those commonly associated with hemodialysis.Conclusion::Darbepoetin alfa intravenously once per week can effectively increase Hb levels and maintain the target Hb levels well, which makes it not inferior to epoetin alfa intravenously twice or three times per week. Darbepoetin alfa shows an efficacy and safety comparable to epoetin alfa for the treatment of renal anemia.

Objective To investigate the clinical treatment of nonpenetrated cornea trauma caused by crops. Methods Clinical data of 128 cases of nonpenetrated cornea trauma caused by crops were retrospectively analyzed. According to the interval time between occurrence of trauma and clinic visiting, the patients were divided into 3 groups:group A (33 cases,<24 h), group B (72 cases, 24 h≤interval time<1 week) and group C (23 cases, ≥ 1 week). The therapeutic effects and prognosis were analyzed. Results There was statistical difference in the incidence of corneal ulcer among group A, group B and group C: 6.1% (2/33), 62.5% (45/72) and 100.0% (23/23), χ2= 52.32, P<0.01. In group B, 12 cases were treated with conjunctival flap covering, 2 cases received keratoplasty and 2 cases undertook enucleation. In group C, 10 cases were treated with conjunctival flap covering, 4 cases received keratoplasty and 2 patients undertook enucleation finally. All the other patients were cured with local debridement and medical treatment. Conclusions Patients with nonpenetrated cornea trauma caused by crops may develop infectious keratitis, and prompt and proper treatment can avoid the secondary infection and improve the outcome. Local debridement in combination with iodophors disinfection can prevent the incidence of infectious keratitis. Conjunctival flap covering is an effective technique in the treatment of corneal ulcer caused by nonpenetrated cornea trauma.